New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
08:48 EDTFMIFoundation Medicine data to have positive effect on reimbursement, says Wedbush
After clinical data on gene fusion detection indicated that such detection led to clinical action in about 15% of patients, Wedbush thinks the 15% level will be more than enough for large payors to recognize the importance of deep tumor profiling in some patients. The firm thinks the recent increase in reimbursement rates for BRCA pricing is positive for long-term FoundationOne reimbursement. Wedbush keeps a $50 price target and Outperform rating on Foundation Medicine.
News For FMI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
15:10 EDTFMIFoundation Medicine to host special shareholder meeting
Subscribe for More Information
March 23, 2015
06:42 EDTFMIFoundation Medicine promotes Steven Kafka to President & COO, Jason Ryan to CFO
Subscribe for More Information
06:32 EDTFMIFoundation Medicine announces board changes in connection to Roche transaction
Foundation Medicine (FMI) announced proposed changes to its board in connection with its pending strategic collaboration with Roche (RHHBY). Under the terms of the agreement with Roche, Foundation Medicine’s board will increase to nine directors upon the closing of the transaction, including three board designees selected by Roche. The pending transaction with Roche remains subject to the satisfaction of certain closing conditions, including the successful completion of the tender offer commenced by Roche on February 2, 2015 and the approval of certain matters at the special meeting of Foundation Medicine stockholders to be held on April 2, 2015. The closing is expected to occur in the second quarter of 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use